IRWD Stock Analysis: Buy, Sell, or Hold?
IRWD - Ironwood Pharmaceuticals, Inc. - Class A
$4.08
0.11 (2.77%)
▲
5d:
-4.9%
30d:
-5.56%
90d:
+12.4%
HOLD
MODERATE Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When IRWD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: IRWD shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: IRWD shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.58
Based on 14.0% avg growth
INTRINSIC VALUE TODAY
$6.57
37.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 3.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: IRWD is currently trading at $4.08, which is considered oversold relative to its 30-day fair value range of $4.12 to $4.35. From a valuation perspective, the stock is trading at a discount (Forward PE: 2.7) compared to its historical average (3.7). Remarkably, the market is currently pricing in an annual earnings decline of 9.9% over the next few years. This pessimistic expectation contrasts with the company's recent 125.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, IRWD is in a strong uptrend. Immediate support is located at $3.94, while resistance sits at $4.48.
Market Sentiment: IRWD scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.10 (+49.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, IRWD is in a strong uptrend. Immediate support is located at $3.94, while resistance sits at $4.48.
Market Sentiment: IRWD scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.10 (+49.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.12 -
$4.35
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (32/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 49.5% below Wall St target ($6.10)
Trading Range Analysis
30-Day Trading Range
$4.12 -
$4.35
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.94
Resistance Level
$4.48
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
2.72
Wall Street Target
$6.10
(+49.5%)
Revenue Growth (YoY)
32.6%
Earnings Growth (YoY)
125.7%
Profit Margin
33.4%
Valuation Discount vs History
-9.9% cheaper
PE vs Historical
2.7 vs 3.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-9.9%
(market-implied from PE analysis)
1-Year Target
$3.68
(-10%)
2-Year Target
$3.31
(-19%)
3-Year Target
$2.98
(-27%)
3-Yr Target (if PE normalizes)
(PE: 3→4)
$4.06
(-1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 24.0%)
$57.64
(+1313%)
Base:
(SPY PE: 2.7, Growth: 24.0%)
$7.77
(+91%)
Bear:
(PE: 2.3, Growth: 24.0%)
$6.61
(+62%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (5x PE), but valuation improves significantly next year (3x PE) as earnings recover.
Trailing PE: 5.16 | Current EPS (TTM): $0.77
Bull Case
$8.51
(+109%)
Analyst growth 94.8%, PE expands to 5.7
Base Case
$7.73
(+90%)
Market implied 94.8%, PE stable at 5.2
Bear Case
$2.70
(-34%)
Severe decline -20.0%, PE contracts to 4.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 2.7 to 3.7
Stabilization Target:
$5.55
(+36.0%)
PE Expansion Potential:
+36.0%
Share & Embed Analysis
Last updated: September 13, 2026 2:44 PM ET
Data refreshes hourly during market hours. Next update: 3:44 PM
Data refreshes hourly during market hours. Next update: 3:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IRWD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary Sh… |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
